Albert Font

Medicine · Health Sciences

20h-index2.2kcitations110works1.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(32), Prostate Cancer Treatment and Research(24), Urinary and Genital Oncology Studies(15), Cancer Treatment and Pharmacology(12), Renal cell carcinoma treatment(10)

Publications110 total

The Toxicology Investigators Consortium 2024 Annual Report
Journal of Medical Toxicology·2026Open Access
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression
International Journal of Molecular Sciences·2025· 2 citedOpen Access
Articles You Might Have Missed
Journal of Medical Toxicology·2025Open Access
Spatial biomarkers of response to neoadjuvant therapy in muscle-invasive bladder cancer: the DUTRENEO trial
2025· 4 citedOpen Access
163 - Evolution of urinary continence after vaginal prolapse surgery: Interim analysis of a multicentric prospective study
Continence·2024Open Access
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
Cancers·2024· 2 citedOpen Access
Supplementary Figure Legends from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Figure 2 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Figure Legends from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Data from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Figure 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Data from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Figure 2 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Table 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Table 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Supplementary Figure 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
2023Open Access
Data from Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
2023Open Access
Data from Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
2023Open Access
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
Journal of Clinical Oncology·2022· 3 cited
Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial.
Journal of Clinical Oncology·2022· 5 cited
page 1 of 6Next →

Frequent Co-authors

Joaquim Bellmunt(14), Begoña Mellado(14), Joan Carles(13), Jesús García-Donás(12), Aranzazu González del Alba(12), Enrique Gallardo(12), Javier Puente(11), Daniel Castellano(9), Núria Laínez(9), José Ángel Arranz(8), Montserrat Domènech(8), Albert Abad(7), Emilio Esteban(7), Miguel Ángel Climent(7), Rafael Rosell(7), Cristina Rodríguez‐Antona(6), J.L. González-Larriba(6), José A. Martínez-Climent(6), Ignacio Durán(6), José Luis Perez‐Gracia(5)